Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Room 7.219, Charlestown, Boston, MA 02129 USA.
J Immunother Cancer. 2017 Mar 21;5:28. doi: 10.1186/s40425-017-0230-9. eCollection 2017.
Chimeric antigen receptor (CAR) T-cell therapy represents a revolutionary treatment for haematological malignancies (i.e. B-ALL). However, the success of this type of treatment has not yet been achieved in solid tumors. One hypothesis is that the immunosuppressive nature of the tumor microenvironment (TME) influences and affects the efficacy of adoptive immunotherapy. Understanding the role of the TME and its interaction with CAR T-cells is crucial to improve the potency of adoptive immunotherapy. In this review, we discuss the strategies and potential combinatorial approaches recently developed in mouse models to enhance the efficacy of CAR T-cells, with particular emphasis on the translational potential of these approaches.
嵌合抗原受体 (CAR) T 细胞疗法代表了血液恶性肿瘤（即 B-ALL）的一种革命性治疗方法。然而，这种治疗方法在实体瘤中的疗效尚未得到证实。一种假设是肿瘤微环境 (TME) 的免疫抑制特性影响和影响了过继免疫疗法的疗效。了解 TME 的作用及其与 CAR T 细胞的相互作用对于提高过继免疫疗法的效力至关重要。在这篇综述中，我们讨论了最近在小鼠模型中开发的增强 CAR T 细胞疗效的策略和潜在组合方法，特别强调了这些方法的转化潜力。
Zotero 插件